Fulgent Genetics, Inc.

NasdaqGM:FLGT 株式レポート

時価総額:US$547.2m

Fulgent Genetics マネジメント

マネジメント 基準チェック /24

Fulgent Geneticsの CEO はMing Hsiehで、 May2016年に任命され、 の在任期間は 8.5年です。 の年間総報酬は$ 5.31Mで、 18.8%給与と81.2%のボーナス(会社の株式とオプションを含む)で構成されています。 は、会社の株式の28.52%を直接所有しており、その価値は$ 156.09M 。経営陣と取締役会の平均在任期間はそれぞれ4.7年と3.8年です。

主要情報

Ming Hsieh

最高経営責任者

US$5.3m

報酬総額

CEO給与比率18.8%
CEO在任期間8.5yrs
CEOの所有権28.5%
経営陣の平均在職期間4.7yrs
取締役会の平均在任期間3.8yrs

経営陣の近況

Shareholders May Be Wary Of Increasing Fulgent Genetics, Inc.'s (NASDAQ:FLGT) CEO Compensation Package

May 10
Shareholders May Be Wary Of Increasing Fulgent Genetics, Inc.'s (NASDAQ:FLGT) CEO Compensation Package

Recent updates

Fulgent Genetics: An NCAV Pick With Profit And Growth Potential

Sep 25

Fulgent Genetics: Core Growth Re-Acceleration Will Be The Critical Catalyst

Sep 09

Some Shareholders Feeling Restless Over Fulgent Genetics, Inc.'s (NASDAQ:FLGT) P/S Ratio

Jul 17
Some Shareholders Feeling Restless Over Fulgent Genetics, Inc.'s (NASDAQ:FLGT) P/S Ratio

Fulgent Genetics: Growth Is Returning

Jun 06

Shareholders May Be Wary Of Increasing Fulgent Genetics, Inc.'s (NASDAQ:FLGT) CEO Compensation Package

May 10
Shareholders May Be Wary Of Increasing Fulgent Genetics, Inc.'s (NASDAQ:FLGT) CEO Compensation Package

Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

May 07
Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

Are Investors Undervaluing Fulgent Genetics, Inc. (NASDAQ:FLGT) By 32%?

Mar 01
Are Investors Undervaluing Fulgent Genetics, Inc. (NASDAQ:FLGT) By 32%?

Fulgent Genetics: Buy Growth Ahead Below Liquidation Value

Feb 21

Subdued Growth No Barrier To Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Price

Jan 17
Subdued Growth No Barrier To Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Price

Is Fulgent Genetics (NASDAQ:FLGT) Using Debt Sensibly?

Dec 14
Is Fulgent Genetics (NASDAQ:FLGT) Using Debt Sensibly?

Fulgent Genetics (NASDAQ:FLGT) Has Debt But No Earnings; Should You Worry?

Aug 09
Fulgent Genetics (NASDAQ:FLGT) Has Debt But No Earnings; Should You Worry?

Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

May 09
Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

Fulgent Genetics (NASDAQ:FLGT) Is Looking To Continue Growing Its Returns On Capital

Apr 19
Fulgent Genetics (NASDAQ:FLGT) Is Looking To Continue Growing Its Returns On Capital

Why We Like The Returns At Fulgent Genetics (NASDAQ:FLGT)

Jan 15
Why We Like The Returns At Fulgent Genetics (NASDAQ:FLGT)

Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?

Dec 28
Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?

What Does The Future Hold For Fulgent Genetics, Inc. (NASDAQ:FLGT)? These Analysts Have Been Cutting Their Estimates

Nov 16
What Does The Future Hold For Fulgent Genetics, Inc. (NASDAQ:FLGT)? These Analysts Have Been Cutting Their Estimates

Why Fulgent Genetics, Inc. (NASDAQ:FLGT) Could Be Worth Watching

Oct 27
Why Fulgent Genetics, Inc. (NASDAQ:FLGT) Could Be Worth Watching

Wait For Fulgent Genetics To Grow Up

Oct 13

We Like Fulgent Genetics' (NASDAQ:FLGT) Returns And Here's How They're Trending

Sep 19
We Like Fulgent Genetics' (NASDAQ:FLGT) Returns And Here's How They're Trending

Fulgent Genetics (NASDAQ:FLGT) Seems To Use Debt Rather Sparingly

Sep 05
Fulgent Genetics (NASDAQ:FLGT) Seems To Use Debt Rather Sparingly

Fulgent Genetics: Poised To Survive Its Post-Covid Hangover

Jul 26

Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Low P/E No Reason For Excitement

Jul 21
Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Low P/E No Reason For Excitement

Fulgent Genetics (NASDAQ:FLGT) Is Investing Its Capital With Increasing Efficiency

Jun 04
Fulgent Genetics (NASDAQ:FLGT) Is Investing Its Capital With Increasing Efficiency

Fulgent Is Putting Its Cash Bonanza To Work

May 15

These 4 Measures Indicate That Fulgent Genetics (NASDAQ:FLGT) Is Using Debt Safely

May 04
These 4 Measures Indicate That Fulgent Genetics (NASDAQ:FLGT) Is Using Debt Safely

Fulgent Genetics: Now The Going Could Get Much Tougher

Apr 10

Fulgent Genetics: COVID Bolstered The Underlying Business

Mar 17

Fulgent Genetics: Somewhat Disappoints With A Marked Slowdown In Its NGS Business

Feb 27

Fulgent Genetics Stock: 35% Off Its Recent Highs - It Is Now A Buy

Feb 09

Fulgent Genetics: Sell Volatility

Jan 26

CEO報酬分析

Fulgent Genetics の収益と比較して、Ming Hsieh の報酬はどのように変化したか?
日付総報酬給与会社業績
Sep 30 2024n/an/a

-US$165m

Jun 30 2024n/an/a

-US$163m

Mar 31 2024n/an/a

-US$166m

Dec 31 2023US$5mUS$1m

-US$168m

Sep 30 2023n/an/a

-US$64m

Jun 30 2023n/an/a

-US$49m

Mar 31 2023n/an/a

-US$26m

Dec 31 2022US$5mUS$948k

US$143m

Sep 30 2022n/an/a

US$272m

Jun 30 2022n/an/a

US$392m

Mar 31 2022n/an/a

US$461m

Dec 31 2021US$6mUS$664k

US$507m

Sep 30 2021n/an/a

US$569m

Jun 30 2021n/an/a

US$493m

Mar 31 2021n/an/a

US$417m

Dec 31 2020US$248kUS$240k

US$214m

Sep 30 2020n/an/a

US$48m

Jun 30 2020n/an/a

US$3m

Mar 31 2020n/an/a

-US$459k

Dec 31 2019US$240kUS$240k

-US$411k

Sep 30 2019n/an/a

-US$2m

Jun 30 2019n/an/a

-US$4m

Mar 31 2019n/an/a

-US$6m

Dec 31 2018US$240kUS$240k

-US$6m

Sep 30 2018n/an/a

-US$5m

Jun 30 2018n/an/a

-US$6m

Mar 31 2018n/an/a

-US$5m

Dec 31 2017US$240kUS$240k

-US$3m

報酬と市場: Mingの 総報酬 ($USD 5.31M ) は、 US市場 ($USD 2.11M ) の同規模の企業の平均を上回っています。

報酬と収益: Mingの報酬は増加しましたが、会社は利益を上げていません。


CEO(最高経営責任者

Ming Hsieh (68 yo)

8.5yrs

在職期間

US$5,309,167

報酬

Mr. Ming Hsieh has been an Independent Director of Fortinet, Inc. since April 2013. He is the Founder of Fulgent Genetics, Inc. and had been its President until May 2022 & serves as its Chief Executive Off...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Ming Hsieh
Chairman & CEO8.5yrsUS$5.31m28.52%
$ 156.1m
Jian Xie
COO & President6.6yrsUS$1.79m1.42%
$ 7.8m
Paul Kim
Chief Financial Officer8.8yrsUS$1.78m0.40%
$ 2.2m
Hanlin Gao
Chief Scientific Officer & Laboratory Director8.2yrsUS$1.49m2.8%
$ 15.3m
Natalie Prescott
General Counsel & Chief Privacy Officer2.5yrsデータなしデータなし
Doreen Ng
VP of Operations & Compliance and GM of Houston Office4.1yrsデータなしデータなし
Jakub Sram
Vice President of Business Development & Sales9.8yrsデータなしデータなし
Ellen Tsui
Vice President of Human Resources2.5yrsデータなしデータなし
Brandon Perthuis
Chief Commercial Officer4.7yrsデータなしデータなし
Lawrence Weiss
Chief Medical Officer3.5yrsデータなしデータなし
Ray Yin
President & Chief Scientific Officer of Fulgent Pharma2yrsデータなしデータなし

4.7yrs

平均在職期間

58yo

平均年齢

経験豊富な経営陣: FLGTの経営陣は 経験豊富 であると考えられます ( 4.7年の平均在職年数)。


取締役

名称ポジション在職期間報酬所有権
Ming Hsieh
Chairman & CEO8.5yrsUS$5.31m28.52%
$ 156.1m
Regina Groves
Independent Non-Employee Director1.8yrsUS$625.60k0.0039%
$ 21.2k
Linda Marsh
Independent Director5.3yrsUS$270.50k0.061%
$ 333.8k
Michael Nohaile
Independent Non-Employee Director2.3yrsUS$268.50k0.0078%
$ 42.6k

3.8yrs

平均在職期間

67yo

平均年齢

経験豊富なボード: FLGTの 取締役会経験豊富 であると考えられます ( 3.8年の平均在任期間)。